Key Points
-Lman1 tissue-specific knockout mice reveal that endothelial cells, not hepatocytes, are the primary source of factor VIII biosynthesis.
-F8 gene expression is heterogeneous among endothelial cell populations in different tissues. 
Abstract

Introduction
Plasma coagulation factor VIII (FVIII) is tightly associated with von Willebrand Factor (VWF).
Though it is well established that VWF is synthesized exclusively in endothelial cells and megakaryocytes, the cellular source of FVIII has been debated for decades. The delayed rise of FVIII in von Willebrand Disease patients infused with VWF demonstrates that VWF and FVIII do not require synthesis in the same cell for complex formation. 1 Dozens of conflicting reports have implicated numerous cell and tissue types as the source of FVIII, though the majority of evidence points to either an endothelial and/or hepatocyte origin of FVIII synthesis. [2] [3] [4] Multiple curative organ transplantation studies in hemophilia A patients and experimental dog models have shown that the liver contributes significantly to FVIII biosynthesis, [5] [6] [7] [8] 10 Similarly, extra-hepatic FVIII production was shown in humans after transplantation of a hemophilia A donor liver into a non-hemophilic recipient. 11 Spleen and lung transplantation has also been shown to restore FVIII plasma levels in several animal models of hemophilia, [12] [13] [14] [15] and FVIII production also has been documented by human purified microvascular endothelial cells from lung in vitro. 16 For personal use only. LMAN1 cause an autosomal recessive bleeding disorder known as combined deficiency of coagulation factors V and VIII (F5F8D). Although FV and FVIII are synthesized at markedly different levels (human plasma FV ~7.0 ug/mL, and FVIII ~200 ng/mL) and potentially in different tissues, loss of the LMAN1 cargo receptor in F5F8D leads to parallel reduction of both of these factors to ~10-15% of normal levels. 22, 23 We previously reported a genetically engineered mouse carrying a gene-trap interruption of the Lman1 gene. 24 Mice homozygous for this gene-trap allele (Lman1 gt1/gt1 ) exhibit reduced FV and
For personal use only. on July 15, 2017. by guest www.bloodjournal.org From FVIII levels that are ~50% of normal, in contrast to the ~10-15% levels in human F5F8D patients. As expected, this modest reduction in FV and FVIII results in a much milder phenotype than reported for hemophilia A mice carrying a F8 gene-targeted allele leading to complete absence of FVIII. 25 We now describe a second, independent conditional Lman1 allele, and analysis of mice with LMAN1 deficiency induced specifically in the hepatocyte or endothelial cell compartments. Deletion of Lman1 only in hepatocytes results in reduced FV, but normal plasma FVIII, whereas endothelial Lman1 deletion reduces FVIII but not FV plasma levels. In addition, analysis of purified, endothelial-specific polysomes by qPCR confirms enrichment of F8 mRNA expression in endothelial cells (relative to total tissue lysates), with considerable heterogeneity in the level of F8 mRNA expression across different vascular beds.
Methods
Lman1 conditional knockout mice
Embryonic stem (ES) cell clone B06 (C57BL/6 genetic background) carrying a conditional Figure 1B ).
Primer set LMAN1 A/B also distinguishes between the Lman1 + and Lman1 cgt alleles ( Figure 1C ).
Genotyping for all animals reported in this study was performed with mouse tail-clip DNA using 
Western blot antibodies
Western blot antibodies were: a monoclonal antibody against human β -actin (Santa Cruz Biotechnology), a monoclonal antibody against the RalA GTPase (Sigma-Aldrich), a goat-antimouse IgG HRP antibody, a polyclonal antibody against LMAN1 (Sigma-Aldrich), and a polyclonal rabbit antibody against the heavy chain of murine FV. 27 FV antigen levels in plasma and platelets were assessed by Western blot analysis using the FV antibody.
Measurement of FV and FVIII levels
Blood was collected into 4% sodium citrate solution (9:1) (Sigma-Aldrich) via inferior vena cava puncture essentially as previously described, 28 under pentobarbital anesthesia (Nembutal Sodium Solution) with a 1 mL syringe. Platelet poor plasma was isolated as previously described, 29 snap frozen, and stored at -80°C. Platelet rich plasma and platelet pellets were isolated and processed as follows: 2mL of room temperature Buffered Saline Glucose Citrate (BSGC) (129 mM NaCl, placed in a 5 mL polypropylene tube, to which was added 1-1.5 mL of whole blood. BSGC was added to a final volume of 4 mL, and then gently mixed by inversion. The tubes were centrifuged at 180 x g for 10 minutes at room temperature. The supernatant (semi-platelet rich plasma) was removed and subjected to a platelet count on an Advia 120 Automated Hematology Analyzer (Siemens), and the number of platelets was normalized between samples before centrifuging in fresh tubes at 700 x g for 10 minutes. Platelet pellets were lysed with Triton-X 100 on ice (final concentration 0.2%) for 30 minutes and frozen as previously described. 24 Plasma and platelet samples from previously described F5 -/-mice carrying either a platelet-or plasma-specific F5 transgene, 30 respectively, were used as experimental controls.
Plasma FV and FVIII activity levels were determined in prothrombin time (PT) and partial thromboplastin time (PTT) based assays, respectively. Individual mouse plasma samples were mixed with human plasma deficient for the respective factor (George King) and analyzed on a KC-4 Coagulation Analyzer (Sigma-Aldrich). A pooled C57BL/6J plasma stock was diluted into human FV or FVIII deficient plasma (George King) to generate a reference standard curve.
RiboTag mice
RiboTag mice 31 (B6.129-Rpl22 tm1.1Psam /J) were a kind gift from Dr. Paul Amieux (University of Washington) and were also obtained from The Jackson Laboratory (stock no. 011029).
Genotyping primers for the RiboTag mice are listed in Supplementary 
RNA isolation
Mice were anesthetized followed by intracardiac perfusion with 12 mL of 100 ug/mL cyclohexamide (Sigma) in PBS, after which tissues were isolated and snap frozen in liquid nitrogen. Immunoprecipitation of endothelial cell-specific polysomes (and bound mRNA) from whole liver, kidney, brain, and heart lysates was performed essentially as previously described, with minor modifications. 31 Frozen tissues were pulverized and the resulting powders were transferred to tubes containing polysome buffer (50 mM Tris, pH 7.5, 100 mM KCl, 12 mM
MgCl2, 1% Nonidet P-40, 1 mM DTT, 200 U/mL Promega RNasin, 1 mg/mL heparin, 100 ug/mL cycloheximide, Sigma protease inhibitor mixture). Cleared lysate was incubated with a purified mouse monoclonal antibody against the hemagglutinin tag (HA.11 clone 16B12, Covance, 3 ug per sample) for 1 hour with rotation at 4°C. Protein G magnetic beads (New England Biolabs) equilibrated in polysome buffer were then added for an additional 30-minute rotated incubation at 4°C. The beads were washed in high salt buffer (50 mM Tris, pH 7.5, 300 mM KCl, 12 mM MgCl2, 1% Nonidet P-40, 1 mM DTT, 100 ug/mL cycloheximide), and ribosome-associated mRNA was subsequently eluted from the beads by adding Qiagen buffer RLT supplemented with 2-mercapto-ethanol (1% v/v). Total RNA was isolated from the whole tissue lysates (input) and immunoprecipitated polyribosome samples with the RNeasy Mini Kit (Qiagen) according to the manufacturer's protocol, and DNase treatment was performed on column (Qiagen). RNA samples were quantified on a spectrophotometer (Nanodrop) and the 1 0 integrity of the RNA was assessed by gel electrophoresis. Total RNA from whole blood of C57BL/6J mice was extracted by using Trizol LS and purified on RNeasy spin columns (Qiagen).
cDNA conversion and qPCR analysis
Total mRNA (100 ng) from input lysates and HA-tagged polysome samples was converted to cDNA with the Superscript First-Strand system (Invitrogen) and oligoDT primers. Gene-specific primers (Supplementary Table 1 Figure 2B ).
These results suggest that endothelial cells are the primary biosynthetic source of FVIII in vivo.
The murine plasma and platelet FV pools are biosynthetically distinct and are derived from synthesis in hepatocytes and megakaryocytes, respectively. 
F8 mRNA is localized to endothelial cells and not hepatocytes
The previously reported RiboTag mouse 31 was used to isolate endothelial cell-specific mRNA for qPCR analysis from a number of different murine tissues. In the absence of Cre-recombinase, RiboTag mice ubiquitously express the wild-type RPL22 ribosomal protein in all cell types.
However, in the presence of Cre-recombinase, RPL22 is fused to a hemagglutinin-tag, which can be used to selectively immunoprecipitate polyribosomes derived only from cells expressing
Cre. 31 Mice homozygous for the RiboTag allele and hemizygous for the Tek-Cre transgene were generated, which should result in expression of the RPL22-HA fusion protein only in endothelial (and hematopoietic) cells.
qPCR analyses of endothelial cell mRNA isolated from unfractionated liver lysates from RiboTag, Tek-Cre + mice (n =4) ( Figure 4A ; Supplementary 
prothrombin (F2), coagulation factor V (F5), coagulation factor VII (F7), and coagulation factor X (F10). In contrast, a 15-22 fold enrichment was observed for gene transcripts that are known to be endothelial-specific, including Cadherin 5 (Cdh5), TEK tyrosine kinase (Tek), Vascular cell adhesion molecule 1 (Vcam1), and von Willebrand factor (Vwf).
Similarly, endothelial cell mRNA from kidney ( Figure 4B qPCR analysis of F8 mRNA levels revealed an unexpected variation in the level of F8 expression across these vascular beds. F8 mRNA transcripts were highly enriched (relative to total tissue lysate) in liver endothelial cells (16.5 fold, p < 2.2 x 10 -4 ), comparable to that of known endothelial-specific genes. F8 transcripts were also enriched in kidney endothelial cells (7.4 fold, p < 1.6 x 10 -3 ). However, no F8 mRNA enrichment was observed in the endothelial cells of brain (0.25 fold, p > 0.1) or heart (0.67 fold, p > 0.15).
Circulating peripheral blood cells do not express F8 mRNA
Since Tek-Cre is also expressed in hematopoietic cells, 34 qRT-PCR was performed on whole blood to exclude contaminating blood as the source of the enriched F8 mRNA in RiboTag, TekCre + tissues. F8 mRNA in the blood was detected at < 2% of the levels in liver and kidney, with normalization to internal control genes Rpl37, Rpl38, and Eif3e (Table 3) . Thus, peripheral blood 30, 33 In the absence of LMAN1, FV levels are reduced in both plasma and platelets in humans and mice. 22, 24, 38 Consistent with these previous data, we observed that mice with Lman1 specifically deleted in by liver transplantation, and presumably also by lung and spleen transplantation. [5] [6] [7] 13, 14 These results are also consistent with the maintenance of normal FVIII levels in patients with parenchymal liver disease in whom the endothelium may still be intact. [42] [43] [44] The variable levels of endothelial cell mRNA enrichment across tissues likely reflects differences in mRNA expression profiles and the relative ratio of endothelial to parenchymal cells in different vascular beds. [45] [46] [47] Though the functional significance of this heterogeneity in FVIII endothelial production is unknown, it could reflect variation in local hemostatic demand across different vascular beds.
Our data are also consistent with several recent publications reporting the relative contributions of hepatocytes and endothelial cells to the plasma FVIII pool. Transplantation of unfractionated liver cells (a mixture of hepatocytes, LSECs, Kupffer cells, and hepatic stellate cells) into the peritoneal cavity of hemophilia A mice corrected the disease, but transplantation of a hepatocyteenriched fraction alone had no effect. 48 Similarly, transplanted normal endothelial cells are able to repopulate the liver endothelium and correct the bleeding phenotype of hemophilia A mice. 49 In addition, FVIII activity levels were found to be 10-to 100-fold higher in human LSECs than in hepatocytes separated by flow cytometry cell sorting. 50 Nonetheless, other studies have detected FVIII in human hepatocytes, [5] [6] [7] [8] 51 and differences in the pathway for FVIII production between humans and mice cannot be excluded.
A growing body of evidence suggests extensive heterogeneity among endothelial cells in vivo. 52 For example, Vwf expression varies widely across different endothelial beds, with different tissue micro-environmental factors regulating its transcription. 53, 54 Similarly, the expression of dozens 1 8 to hundreds of genes may vary among different specialized vascular beds. 55 While we observed modest variation in the expression levels of Vwf and 3 other endothelial-specific genes in our studies of lung, kidney, heart, and brain endothelial cells, we observed large differences in F8 gene expression amongst these four tissues. where F8 mRNA transcripts were detected in endothelial cells from liver and glomeruli, but not in the testis, spleen, muscle, brain, lung, heart, or bone marrow. 45 This heterogeneity of endothelial cell gene expression has important implications, not only for FVIII biosynthesis, but also for regulation of other tissue-specific endothelial cell functions. 56, 57 The finding that F8 and Vwf are both highly expressed in endothelial cells likely confers a regulatory mechanism for FVIII biosynthesis, consistent with previous reports that the coexpression of F8 and Vwf in vitro result in increased stable accumulation of FVIII activity. 58 Finally, the establishment of endothelial cells as the primary site of FVIII biosynthesis also has important implications for the treatment of hemophilia A, particularly for gene-targeting approaches directed specifically to endothelial cells.
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For (17) 25% (18) 19% (14) 32% ( (16) 28% (23) 26.5% (22) 26.5% (22) 0.7 (n.s.)
The chi-squared test (df = 3) was based upon an expected genotype ratio of 3:1, with Lman1 fl/fl /Cre + mice expected to represent 25% of the offspring from each mating, and all other genotypes cumulatively accounting for 75% of offspring. To evaluate the potential contribution of blood contamination to transcript levels of endothelial-specific genes, the tissue lysates of either the kidney or liver samples were set as a reference and the , Alb-Cre + mice. The lower molecular weight band observed in the heart samples represents a non-specific band due to cross-reactivity with the LMAN1 antibody, since this same band is observed in the heart tissue of ubiquitous Lman1 knockout mice (not shown). (A) Platelet-poor plasma (equal volume) and (B) isolated platelets (equal number) from conditional Lman1 knockout mice and littermate control mice were analyzed for relative FV antigen levels by Western blot. The same plasma samples were run twice as duplicates. Plasma IgG serves as a loading control for the plasma samples, and β -actin serves as a loading control for platelets. Three adult mice were analyzed per genotype. Plasma from F5 -/-mice carrying a platelet-specific F5 transgene 30 was included as a negative control for the plasma samples. Similarly, platelets isolated from a F5 -/-mouse carrying a hepatocyte-specific F5 transgene 30 were included as a negative control for the platelet samples. 
